RPRX Royalty Pharma plc - Class A

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY. The company has class B common shares outstanding that are privately held.

$42.30  -1.28 (-2.93%)
As of 03/04/2021 15:59:38 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Large cap
Health Care
Biotechnology
USA
United Kingdom
12/31/1997
388,132,400
1,925,642
$16,910,928,668
1.07%
SEC Edgar Online
10-Q
10-K
G7709Q104
GB00BMVP7Y09
BMVP7Y0

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
31.99
-1,320.30
8.04
20.23%
46.37%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy